AFIRME
AFIRME
A clinical trial assessing chronic platelet inhibition in patients with acute coronary syndromes treated with oral IIb/IIIa inhibitors—Kerval™.Primary endpoint Bleeding, platelet aggregation inhibition.
Conclusion Chronic platelet inhibition has a low rate of bleeding, may be associated with thrombocytopenia and inhibits platelets less in acute coronary syndrome.